Prospective follow-up study of adalimumab treatment in ankylosing spondylitis: efficacy with focus on uveitis

Prospective follow-up study of adalimumab treatment in ankylosing spondylitis: efficacy with focus on uveitis - Adalimumab, uveitis and ankylosing spondylitis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30515

Enrollment

100

Registered

2007-01-18

Start date

2007-03-30

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing spondylitis Bechterew's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Ankylosing spondylitis according to the modified New York criteria, who will start with adalimumab.

Exclusion criteria

Exclusion criteria: 1. Persistent chronic or active infections 2. History of amlignancy 3. Immuno-compromised conditions. 4. History of central nervous system (CNS) demyelinating disease. 5. Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study. 6. Known history of allergic reaction or significant hypersensitivity to the constituents of adalimumab.

Design outcomes

Primary

Measure	Time frame
Primary: - ASAS 20% response - occurrence of attacks of uveitis.	—

Secondary

Measure	Time frame
Secondary: adverse events, improvement of mobility, swollen joints, inflammatory markers, and radiographic progression.	—

Countries

Netherlands

Outcome results